RecruitingPhase 2NCT07347314
Enfortumab Vedotin in Patients With Advanced Small Bowel Adenocarcinoma Refractory or Intolerant to Platinum-based Combination Therapy
Studying Rare carcinoma of small intestine
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Center, Japan
- Intervention
- Enfortumab vedotin(drug)
- Enrollment
- 27 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2028
Study locations (3)
- Kyushu University Hospital, Fukuoka, Japan
- Osaka International Cancer Institute, Osaka, Japan
- National Cancer Center Hospital, Tokyo, Japan
Collaborators
Astellas Pharma Inc
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07347314 on ClinicalTrials.govOther trials for Rare carcinoma of small intestine
Additional recruiting or active studies for the same condition.